Silexion Therapeutics Reports $4.2 Million Net Loss for First Half of 2025

Silexion Therapeutics Corp reported a net loss of $4.2 million for the six months ended June 30, 2025, compared to a loss of $2.9 million for the same period in 2024. The company's total operating expenses increased to $3.9 million from $2.6 million year-over-year, driven primarily by a significant rise in general and administrative costs, which surged to $2.3 million from $0.9 million. Research and development expenses slightly decreased to $1.6 million from $1.7 million, reflecting a shift in focus from subcontractor expenses to payroll-related costs as the company expanded its workforce following its business combination.

In terms of financial position, Silexion's cash and cash equivalents rose to $3.5 million as of June 30, 2025, up from $1.3 million at the end of 2024. The increase was attributed to successful financing activities, including a public offering that generated approximately $5 million in gross proceeds and additional funds from warrant exercises. The company has utilized an equity line of credit (ELOC) to raise a total of $3.1 million since the business combination, which closed in August 2024.

Strategically, Silexion has been focused on advancing its lead product candidate, SIL204, a second-generation small interfering RNA (siRNA) therapy targeting the KRAS oncogene, which is implicated in various cancers, including pancreatic cancer. The company is preparing for clinical trials and has plans to apply for Orphan Drug Designation in both the U.S. and EU. Silexion's operational metrics indicate a growing workforce, with an increase in employee-related obligations reflecting its commitment to expanding its research and development capabilities.

Despite these developments, Silexion faces significant challenges, including ongoing operating losses and the need for additional capital to fund its operations. The company has expressed substantial doubt about its ability to continue as a going concern without securing further financing. Management is actively exploring various funding options, including public and private equity offerings, to ensure sufficient liquidity for its ongoing and future operations. The outlook remains cautious, with expectations of continued losses as the company invests heavily in its clinical development programs.